Accent Therapeutics: $75 Million To Pioneer A New Class Of Small Molecule Precision Cancer Therapies
By Amit Chowdhry ● Jan 23, 2024
Accent Therapeutics - a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies - recently announced the completion of a $75 million Series C financing. The funding was led by Mirae Asset Capital Life Science, with participation from other new investors, Mirae Asset Capital, Mirae Asset Venture Investment, Bristol Myers Squibb and Johnson & Johnson Innovation – JJDC and all existing investors, including The Column Group, Atlas Venture, Droia Ventures, GV, EcoR1 Capital, AbbVie Ventures, The Mark Foundation for Cancer Research, Timefolio Capital (formerly known as NS Investment) and others.